[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586496":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":33,"locations":41,"responsibleParty":55,"collaborators":32,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":32,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":32,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":32,"overallStatus":77,"whyStopped":32,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm-A","EXPERIMENTAL","Period 1 : Test Drug (AD-120), Period 2 : Reference Drug (AD-120A)",[13,14],"Drug: AD-120A","Drug: AD-120",{"label":16,"type":10,"description":17,"interventionNames":18},"Arm-B","Period 1 : Reference Drug (AD-120A), Period 2 : Test Drug (AD-120)",[13,14],[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","AD-120A","Administered before the breakfast during 7 days, Oral, Tablet",[9,16],[26],"Reference Drug",{"type":21,"name":28,"description":23,"armGroupLabels":29,"otherNames":30},"AD-120",[9,16],[31],"Test drug",null,[34,39],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"Hanna Yang","CONTACT","+82-31-891-6918","hnyang@addpharma.co.kr",{"name":40,"role":36,"phone":32,"phoneExt":32,"email":32},"Seung Hwan Lee, M.D., Ph.D.",[42],{"facility":43,"status":32,"city":44,"state":32,"zip":32,"country":45,"countryCode":32,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Seoul National University Hospital","Seoul","South Korea",{"type":47,"coordinates":48},"Point",[49,50],126.9784,37.566,{"lat":50,"lon":49},[53],{"name":54,"role":36,"phone":32,"phoneExt":32,"email":32},"Seunghwan Lee Lee, M.D.,PhD",{"type":56,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100586496","phase-1-a-study-to-compare-pkpd-characteristics-and-safety-profiles-between-ad-120-and-ad-120a-100586496",false,"NCT06916130","A Study to Compare PK\u002FPD Characteristics and Safety Profiles Between AD-120 and AD-120A","A Randomized, Open-label, Multiple Oral-dose, 2x2 Crossover Clinical Trial to Compare the Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a AD-120 and AD-120A in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body weight equal to or greater than 50.0kg and equal to or less than 90.0kg and Body mass index (BMI) between 18.5 kg\u002Fm2 and 29.9 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 and equal to or less than 50 in healthy volunteers at the time of screening visit\n* Negative result from Serum Helicobacter pylori antibody at the time of screening visit\n\nExclusion Criteria:\n\n* Patients with trouble performing pH monitor catheter",true,"ALL","19 Years","50 Years",{"count":69,"type":70},48,"ESTIMATED","INTERVENTIONAL",[73],"PHASE1","Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-120 in healthy subjects.",[76],"Gastroesophageal Reflux Disease (GERD)","NOT_YET_RECRUITING","2025-03-31",{"date":80,"type":81},"2025-04-08","ACTUAL",{"date":83,"type":70},"2025-04-21",{"date":85,"type":70},"2025-09-01",{"name":5,"class":6},1]